Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles from Taipei
Based on 159 articles published since 2008
||||

These are the 159 published articles about Psoriasis that originated from Taipei during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7
1 Editorial Pressing onward towards the goal: Engineering intelligent systems to improve clinical care. 2016

Wu, Chieh-Chen / Lu, Richard / Yang, Hsuan-Chia / Li, Yu-Chuan Jack. ·Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, Taipei, Taiwan. · Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, Taipei, Taiwan; International Center for Health Information Technology (ICHIT), Taipei Medical University, Taiwan. · Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, Taipei, Taiwan; Institute of Biomedical Informatics, National Yang Ming University, Taiwan. · Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, Taipei, Taiwan; International Center for Health Information Technology (ICHIT), Taipei Medical University, Taiwan; Chair, Department of Dermatology, Wan Fang Hospital, Taipei, Taiwan. Electronic address: jack@tmu.edu.tw. ·Comput Methods Programs Biomed · Pubmed #26915273.

ABSTRACT: -- No abstract --

2 Review Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work. 2018

Ho, Po-Han / Tsai, Tsen-Fang. ·Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. ·J Dermatol · Pubmed #30230584.

ABSTRACT: Juvenile generalized pustular psoriasis (GPP) is rare and often resistant to conventional systemic therapy such as methotrexate, retinoic acid and cyclosporin A. GPP can be induced by deficiency of interleukin (IL)-36 receptor antagonist (DITRA). No standardized guidelines are available for juvenile GPP or DITRA, and a uniformly safe and effective biologic agent has not been identified. However, multiple biologics approved for use in plaque-type psoriasis have also been used in GPP. Herein, we report a case of a 6-year-old Taiwanese boy with GPP and homozygous mutation at c.115+6T>C within the IL-36 receptor antagonist (IL36RN) gene, who was treated successfully with secukinumab after failure of prior methotrexate, acitretin, cyclosporin A, etanercept and adalimumab. Similar to two previously reported non-adult cases of GPP successfully treated with secukinumab, our case also demonstrated a history of repeated treatment failures with several conventional oral systemic agents and biologics. Different from these two cases, however, ours is the first of juvenile GPP successfully treated with secukinumab monotherapy, without using other systemic agent concurrently during the use of secukinumab.

3 Review Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies. 2018

Chyuan, I-Tsu / Chen, Ji-Yih. ·Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan. · Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. · Department of Medicine, Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. · College of Medicine, Chang Gung University, Taoyuan, Taiwan. ·Mediators Inflamm · Pubmed #29670461.

ABSTRACT: Spondyloarthropathy (SpA) is a unique type of joint inflammation characterized by coexisting erosive bone damage and pathological new bone formation. Previous genetic association studies have demonstrated that several cytokine pathways play a critical role in the pathogenesis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and other types of SpA. In addition to several well-known proinflammatory cytokines, recent studies suggest that IL-17 plays a pivotal role in the pathogenesis of SpA. Further evidence from human and animal studies have defined that IL-17 and IL-17-producing cells contribute to tissue inflammation, autoimmunity, and host defense, leading to the following pathologic events associated with SpA. Recently, several clinical trials targeting IL-17 pathways demonstrated the positive response of IL-17 blockade in treating AS, indicating a great potential of IL-17-targeting therapy in SpA. In this review article, we have discussed the contributing role of IL-17 and different IL-17-producing cells in the pathogenesis of SpA and provided an outline of therapeutic application of the IL-17 blockade in the treatment of SpA. Other targeted cytokines associated with IL-17 axis in SpA will also be included.

4 Review Murine models of psoriasis and their usefulness for drug discovery. 2018

Chuang, Shih-Yi / Lin, Chih-Hung / Sung, Calvin T / Fang, Jia-You. ·a Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine , Chang Gung University of Science and Technology , Taoyuan , Taiwan. · b Center for General Education , Chang Gung University of Science and Technology , Taoyuan , Taiwan. · c School of Medicine , University of California , Riverside , USA. · d Pharmaceutics Laboratory, Graduate Institute of Natural Products , Chang Gung University , Taoyuan , Taiwan. · e Chinese Herbal Medicine Research Team, Healthy Aging Research Center , Chang Gung University , Taoyuan , Taiwan. · f Department of Anesthesiology , Chang Gung Memorial Hospital , Taoyuan , Taiwan. ·Expert Opin Drug Discov · Pubmed #29663834.

ABSTRACT: INTRODUCTION: Psoriasis is an autoimmune skin disease characterized by red plaques with silver or white multilayered scales with a thickened acanthotic epidermis. Using mouse models of cutaneous inflammation, IL-23/Th17 was identified to have a potential key role in psoriasis. New treatments to slow this inflammatory skin disorder are urgently needed. To aid their discovery, a psoriasis animal model mimicking human psoriasis is urgently needed for their early preclinical evaluation. Areas covered: The authors review animal models of psoriasis and analyze the features and molecular mechanisms involved in these mouse models. The application of various mouse models of psoriasis for drug discovery and development has also been reviewed and the possible molecular targets in psoriasis for future anti-psoriatic drug design is discussed. Expert opinion: So far, it has been difficult to create an animal model that exactly simulates a human disease or condition. The xenotransplantation model is regarded as the closest to incorporating the complete genetic, phenotypic, and immunopathogenic processes of psoriasis. However, the imiquimod (IMQ)-induced model is the most prevalent among psoriatic mouse models due to its ease of use, convenience, and low cost. Further efforts to develop psoriasis-like skin models in mice are needed for the study and treatment of this complex disease.

5 Review Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. 2018

Kuo, C-M / Tung, T-H / Wang, S-H / Chi, C-C. ·School of Medicine, Tzu Chi University, Hualien, Taiwan. · Department of Medical Research and Education, Cheng Hsin General Hospital, Taipei, Taiwan. · Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan. · Graduate Institute of Applied Science and Engineering, College of Science and Engineering, Fu Jen Catholic University, New Taipei, Taiwan. · Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. · Department of Dermatology, Chang Gung Memorial Hospital, Chiayi, Taiwan. · College of Medicine, Chang Gung University, Taoyuan, Taiwan. ·J Eur Acad Dermatol Venereol · Pubmed #29136293.

ABSTRACT: The effects of tofacitinib in treating moderate-to-severe plaque psoriasis were unclear. We aimed to assess the effects of tofacitinib in treating moderate-to-severe plaque psoriasis. We searched PubMed, Cochrane Central Register of Controlled Trials and EMBASE for relevant randomized controlled trials (RCTs) and conducted a systematic review and meta-analysis. Four RCTs with 2724 participants were included. Compared to placebo, tofacitinib significantly improved psoriasis {≥75% reduction in the Psoriasis Area and Severity Index score: 5 mg BID: risk difference (RD) 0.32 [95% confidence interval (CI) 0.28-0.35], 10 mg BID: RD 0.51 (95% CI 0.43-0.58); ≥90% reduction in the Psoriasis Area and Severity Index score: 5 mg BID: RD 0.19 (95% CI 0.17-0.22), 10 mg BID: RD 0.36 (95% CI 0.31-0.42); Physician's Global Assessment 0/1: 5 mg BID: RD 0.31 (95% CI 0.27-0.35), 10 mg BID: RD 0.48 (95% CI 0.44-0.53)} and participants' life quality [Dermatology Life Quality Index 0/1: 5 mg BID: RD 0.24 (95% CI 0.20-0.2), 10 mg BID: RD 0.36 (95% CI 0.33-0.40)]. Tofacitinib was associated with an increase in minor adverse events [upper respiratory tract infection: 5 mg BID: RD 0.02 (95% CI 0.00-0.03), 10 mg BID: RD 0.02 (95% CI 0.00-0.04); hypercholesterolaemia: 5 mg BID: RD 0.02 (95% CI 0.01-0.04), 10 mg BID: RD 0.02 (95% CI 0.01-0.04)]. In conclusion, tofacitinib may be a treatment option for moderate-to-severe plaque psoriasis that is unresponsive to other therapies and patients who are intolerable to other therapies or prefer oral medications.

6 Review Tofacitinib in psoriatic arthritis. 2017

Wang, Ting-Shun / Tsai, Tsen-Fang. ·Division of Dermatology, Chung Shan Medical University Hospital, Taichung, Taiwan. · Department of Dermatology, National Taiwan University Hospital & National Taiwan University College of Medicine, Taipei, Taiwan. ·Immunotherapy · Pubmed #28967798.

ABSTRACT: Psoriatic arthritis is a heterogeneous disease that has been difficult to manage until the recent advent of biologics. However, there are still unmet medical needs for newer agents. Tofacitinib is a Janus family of kinases inhibitor approved for treating rheumatoid arthritis in many countries and psoriasis in Russia. We reviewed the evidences of tofacitinib in psoriatic arthritis treatment. The efficacy and safety profiles result from Phase III clinical trials (OPAL BROADEN and OPAL BEYOND) and one open-label extension study (OPAL BALANCE). Both tofacitinib 5 or 10 mg twice a day were superior to placebo for American College of Rheumatology 20% improvement criteria response at 3 months and showed significant improvement of skin, enthesitis and dactylitis. Tofacitinib is a promising treatment option for psoriatic arthritis.

7 Review Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation. 2017

Lai, Chao-Yang / Su, Yu-Wen / Lin, Kuo-I / Hsu, Li-Chung / Chuang, Tsung-Hsien. ·Immunology Research Center, National Health Research Institutes, Miaoli 35053, Taiwan. · Genomics Research Center, Academia Sinica, Taipei 115, Taiwan. · Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei 10002, Taiwan. · Program in Environmental and Occupational Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. ·J Immunol Res · Pubmed #28894754.

ABSTRACT: Psoriasis is a chronic inflammatory autoimmune disease that can be initiated by excessive activation of endosomal toll-like receptors (TLRs), particularly TLR7, TLR8, and TLR9. Therefore, inhibitors of endosomal TLR activation are being investigated for their ability to treat this disease. The currently approved biological drugs adalimumab, etanercept, infliximab, ustekinumab, ixekizumab, and secukizumab are antibodies against effector cytokines that participate in the initiation and development of psoriasis. Several immune modulatory oligonucleotides and small molecular weight compounds, including IMO-3100, IMO-8400, and CPG-52364, that block the interaction between endosomal TLRs and their ligands are under clinical investigation for their effectiveness in the treatment of psoriasis. In addition, several chemical compounds, including AS-2444697, PF-05387252, PF-05388169, PF-06650833, ML120B, and PHA-408, can inhibit TLR signaling. Although these compounds have demonstrated anti-inflammatory activity in animal models, their therapeutic potential for the treatment of psoriasis has not yet been tested. Recent studies demonstrated that natural compounds derived from plants, fungi, and bacteria, including mustard seed,

8 Review Acupuncture-Related Techniques for Psoriasis: A Systematic Review with Pairwise and Network Meta-Analyses of Randomized Controlled Trials. 2017

Yeh, Mei-Ling / Ko, Shu-Hua / Wang, Mei-Hua / Chi, Ching-Chi / Chung, Yu-Chu. ·1 Graduate Institute of Integration of Traditional Chinese Medicine with Western Nursing, National Taipei University of Nursing and Health Sciences , Taipei, Taiwan, Republic of China . · 2 Chong-Ren Hospital , Miaoli, Taiwan, Republic of China . · 3 School of Nursing, National Taipei University of Nursing and Health Sciences , Taipei, Taiwan, Republic of China . · 4 Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Chang Gung University College of Medicine , Taoyuan, Taiwan, Republic of China . · 5 Department of Nursing, Yuanpei University of Medical Technology , Hsinchu, Taiwan, Republic of China . ·J Altern Complement Med · Pubmed #28628749.

ABSTRACT: OBJECTIVE: There has be a large body of evidence on the pharmacological treatments for psoriasis, but whether nonpharmacological interventions are effective in managing psoriasis remains largely unclear. This systematic review conducted pairwise and network meta-analyses to determine the effects of acupuncture-related techniques on acupoint stimulation for the treatment of psoriasis and to determine the order of effectiveness of these remedies. METHODS: This study searched the following databases from inception to March 15, 2016: Medline, PubMed, Cochrane Central Register of Controlled Trials, EBSCO (including Academic Search Premier, American Doctoral Dissertations, and CINAHL), Airiti Library, and China National Knowledge Infrastructure. Randomized controlled trials (RCTs) on the effects of acupuncture-related techniques on acupoint stimulation as intervention for psoriasis were independently reviewed by two researchers. RESULTS: A total of 13 RCTs with 1,060 participants were included. The methodological quality of included studies was not rigorous. Acupoint stimulation, compared with nonacupoint stimulation, had a significant treatment for psoriasis. However, the most common adverse events were thirst and dry mouth. Subgroup analysis was further done to confirm that the short-term treatment effect was superior to that of the long-term effect in treating psoriasis. Network meta-analysis identified acupressure or acupoint catgut embedding, compared with medication, and had a significant effect for improving psoriasis. It was noted that acupressure was the most effective treatment. CONCLUSIONS: Acupuncture-related techniques could be considered as an alternative or adjuvant therapy for psoriasis in short term, especially of acupressure and acupoint catgut embedding. This study recommends further well-designed, methodologically rigorous, and more head-to-head randomized trials to explore the effects of acupuncture-related techniques for treating psoriasis.

9 Review Image Gallery: Resolution of lichen striatus in a patient with coexisting chronic plaque psoriasis and vitiligo during secukinumab treatment. 2017

Yang, C-W / Tsai, T-F. ·Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. ·Br J Dermatol · Pubmed #28504405.

ABSTRACT: -- No abstract --

10 Review Risk of Suicidality in People with Psoriasis: A Systematic Review and Meta-Analysis of Cohort Studies. 2017

Chi, Ching-Chi / Chen, Ting-Hao / Wang, Shu-Hui / Tung, Tao-Hsin. ·Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. · Department of Dermatology, Chang Gung Memorial Hospital, Chiayi, Chiayi, Taiwan. · College of Medicine, Chang Gung University, Taoyuan, Taiwan. · Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan. · Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan. · Graduate Institute of Applied Science and Engineering, College of Science and Engineering, Fu Jen Catholic University, New Taipei, Taiwan. · Department of Medical Research and Education, Cheng Hsin General Hospital, 45, Cheng Hsin St, Pai-Tou, Taipei, 11220, Taiwan. ch2876@chgh.org.tw. · Department of Public Health, Fu Jen Catholic University, New Taipei, Taiwan. ch2876@chgh.org.tw. ·Am J Clin Dermatol · Pubmed #28409490.

ABSTRACT: BACKGROUND: Psoriasis has been associated with psychiatric disorders such as depression and anxiety, but its relationship with suicidality (including suicide, suicide attempt, and suicidal ideation) is unclear. OBJECTIVE: Our objective was to assess the risk of suicide, suicide attempt, suicidal ideation, and suicidality in people with psoriasis. METHODS: We conducted a systematic review and meta-analysis of cohort studies examining the risk of suicide, suicide attempt, suicidal ideation, and suicidality in people with psoriasis. We searched the Cochrane Library, PubMed, and EMBASE from inception to 24 March 2017. Two authors independently selected studies, assessed the quality of included studies, and extracted data. Any disagreement was resolved by discussion with a third author. RESULTS: Five population-based cohort studies were included and considered to be of high quality. We found no increase in the risk of suicide (risk ratio [RR] 1.13; 95% confidence interval [CI] 0.87-1.46), suicide attempt (RR 1.25; 95% CI 0.89-1.75), or suicidality (RR 1.26; 95% CI 0.97-1.64) among people with psoriasis. In the stratified analysis, we also found no increase in suicide, suicide attempt, and suicidality among people with either severe or mild psoriasis. CONCLUSIONS: The available limited, very low-quality evidence does not support an association between psoriasis and suicidal thought and behavior. Further studies that provide data for different age and sex groups are needed to clarify whether a subgroup of patients with psoriasis has an elevated risk of suicidality.

11 Review Risks for Staphylococcus aureus colonization in patients with psoriasis: a systematic review and meta-analysis. 2017

Ng, C Y / Huang, Y H / Chu, C F / Wu, T C / Liu, S H. ·Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan. · College of Medicine, Chang Gung University, Gueishan District, Taoyuan City, Taiwan. · Graduate Institute of Clinical Medical Sciences, Chang Gung University, Gueishan District, Taoyuan City, Taiwan. · Department of Family Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan. ·Br J Dermatol · Pubmed #28160277.

ABSTRACT: Evidence on whether patients with psoriasis have a higher risk for staphylococcal colonization than healthy controls remains controversial. To synthesize the current literature, we performed a systematic review on the prevalence and relative risk (RR) of Staphylococcus aureus colonization in patients with psoriasis. We modified the QUADAS-2 instrument to assess the reporting quality of individual studies and applied random-effects models in meta-analysis. Overall we identified 21 eligible studies, of which 15 enrolled one or more comparison groups. The pooled prevalence of staphylococcal colonization in patients with psoriasis was 35·3% [95% confidence interval (CI) 25·0-45·6] on lesional skin and 39·2% (95% CI 33·7-44·8) in the nares. Patients with psoriasis were 4·5 times more likely to be colonized by S. aureus than healthy controls were on the skin (RR 5·54, 95% CI 3·21-9·57) and 60% more in the nares (RR 1·60, 95% CI 1·11-2·32). Cutaneous and nasal colonization by meticillin-resistant S. aureus also appeared higher in patients with psoriasis (pooled prevalence 8·6%) than in healthy controls (2·6%), yet the difference was not statistically significant (P = 0·74). In contrast, despite of a similar risk for nasal staphylococcal colonization (RR 0·67, 95% CI 0·38-1·18), patients with psoriasis were less likely to carry S. aureus on lesional skin than atopic patients (RR 0·64, 95% CI 0·40-1·02). In summarizing the current literature, we found that patients with psoriasis were at an increased risk for staphylococcal colonization compared with healthy individuals. Prospective studies on how bacterial loads correlate with disease activity can guide the clinical management of bacterial colonization while preventing the emergence of drug-resistant strains.

12 Review Managing Scalp Psoriasis: An Evidence-Based Review. 2017

Wang, Ting-Shun / Tsai, Tsen-Fang. ·Department of Dermatology, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan. · Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, #7, Chung-Shan South Road, Taipei, Taiwan. · Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, #7, Chung-Shan South Road, Taipei, Taiwan. tftsai@yahoo.com. ·Am J Clin Dermatol · Pubmed #27650520.

ABSTRACT: BACKGROUND: Scalp psoriasis is commonly the initial presentation of psoriasis, and almost 80 % of patients with psoriasis will eventually experience it. OBJECTIVE: Although several systematic reviews and guidelines exist, an up-to-date evidence-based review including more recent progress on the use of biologics and new oral small molecules was timely. METHODS: Of the 475 studies initially retrieved from PubMed and the 845 from Embase (up to May 2016), this review includes 27 clinical trials, four papers reporting pooled analyses of other clinical trials, ten open-label trials, one case series, and two case reports after excluding non-English literature. RESULTS: To our knowledge, few randomized controlled trials (RCTs) are conducted specifically in scalp psoriasis. Topical corticosteroids provide good effects and are usually recommended as first-line treatment. Calcipotriol-betamethasone dipropionate is well tolerated and more effective than either of its individual components. Localized phototherapy is better than generalized phototherapy on hair-bearing areas. Methotrexate, cyclosporine, fumaric acid esters, and acitretin are well-recognized agents in the treatment of psoriasis, but we found no published RCTs evaluating these agents specifically in scalp psoriasis. Biologics and new small-molecule agents show excellent effects on scalp psoriasis, but the high cost of these treatments mean they may be limited to use in extensive scalp psoriasis. CONCLUSIONS: More controlled studies are needed for an evidence-based approach to scalp psoriasis.

13 Review A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects. 2016

Tsai, Ya C / Tsai, Tsen F. ·Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan - tftsai@yahoo.com. ·G Ital Dermatol Venereol · Pubmed #26889727.

ABSTRACT: INTRODUCTION: Biologics are increasingly used in the treatment of moderate to severe psoriasis. However, most of the pivotal studies were performed mainly in western countries. The purpose of this review article was to compare the differences of clinical trial results between Asian and Western subjects of psoriasis regarding baseline demographics, efficacy, dermatology life quality index, safety and antidrug antibodies. EVIDENCE ACQUISITION: In this review article, we searched the PubMed/Medline, ClinicalTrials.gov, and posters from main dermatologic meetings. EVIDENCE SYNTHESIS: Only randomized controlled trial results or trial results for registration purposes of etanercept, adalimumab, infliximab, ustekinumab, secukinumab, brodalumab, ixekizumab, guselkumab, tofacitinib, and apremilast are included. CONCLUSIONS: Asian subjects were generally 15-20 Kgs lighter, with fewer psoriatic arthritis, shorter disease duration since diagnosis, and higher baseline severity compared to western subjects. Better efficacy had been found in some studies such as secukinumab, brodalumab, ixekizumab, and tofacitinib in Japanese groups. The safety in Asian trials was generally compatible with the pivotal studies, except for the occurrence of active tuberculosis in the infliximab trial in China. Additional indications of pustular and erythrodermic psoriasis are approved in Japan for some of the agents based on phase II/III studies.

14 Review Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system. 2014

Wang, Shu-Hui / Chi, Ching-Chi / Hu, Sindy. ·Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan; Department of Healthcare Administration, Oriental Institute of Technology, New Taipei, Taiwan; Department of Cosmetic Science, Chang Gung University of Science and Technology, Taoyuan, Taiwan. ·Int J Dermatol · Pubmed #24738910.

ABSTRACT: BACKGROUND: Biologic therapies are more effective than conventional therapies in the treatment of psoriasis, but they are also more costly. OBJECTIVES: The aim of this study was to compare the cost-efficacy of etanercept, adalimumab, and ustekinumab therapies in the treatment of moderate to severe psoriasis in a Taiwanese setting. METHODS: We conducted a meta-analysis of randomized, placebo-controlled trials to calculate the incremental efficacy of etanercept, adalimumab, and ustekinumab, respectively, in affecting a reduction of ≥75% in score on the Psoriasis Area and Severity Index (PASI 75). The base, best case, and worst case incremental cost-effectiveness ratios (ICERs) for one subject to achieve PASI 75 were calculated for the purposes of economic analysis. RESULTS: One-year ICERs per PASI 75 responder were US$ 39,709 (best scenario US$ 36,400; worst scenario US$ 43,680), US$ 23,711 (best scenario US$ 22,633; worst scenario US$ 25,319), and US$ 26,329 (best scenario US$ 24,780; worst scenario US$ 27,623) for etanercept, adalimumab, and ustekinumab, respectively. Two year ICERs per PASI 75 responder were US$ 71,973 (best scenario US$ 65,975; worst scenario US$ 79,170), US$ 62,665 (best scenario US$ 59,817; worst scenario US$ 66,914), and US$ 52,657 (best scenario US$ 49,560; worst scenario US$ 55,427) for etanercept, adalimumab, and ustekinumab, respectively. CONCLUSIONS: In a Taiwanese setting, adalimumab and ustekinumab had lower 1-year costs per PASI 75 responder than etanercept, and ustekinumab had the lowest 2-year cost per PASI 75 responder.

15 Review Intralesional therapy for psoriasis. 2013

Wang, Ting-Shun / Tsai, Tsen-Fang. ·Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China. ·J Dermatolog Treat · Pubmed #22390539.

ABSTRACT: Localized resistant plaques of psoriasis often remain despite highly effective anti-psoriasis treatment. Intralesional therapy is often used to treat various malignant, infectious or inflammatory cutaneous diseases, including psoriasis. Despite the presence of many review articles on the treatment of psoriasis, no articles exist which review the use of intralesional therapy for psoriasis. In this article, we review the published literatures of intralesional therapy for psoriasis. Corticosteroids, methotrexate, cyclosporin, biologics, botulinum toxin type-A, 15-hydroxyeicosatetraenoic acid, and chemotherapy agents such as 5-fluorouracil are discussed. Also, agents which may be used intralesionally and have the potential to treat psoriasis will also be reviewed such as bleomycin, vincristine or vinblastine, mitomycin-C, aminophylline, 5-aminolevulinic acid, rituximab, bevacizumab and pentoxifylline are included.

16 Review Psoriasis and cardiovascular comorbidities with emphasis in Asia. 2012

Chu, T W / Tsai, T F. ·Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan. tftsai@yahoo.com ·G Ital Dermatol Venereol · Pubmed #22481582.

ABSTRACT: Psoriasis is traditionally considered a skin-specific disease with the exception of coexisting psoriatic arthritis. However, growing evidence suggests a link between psoriasis and other comorbidities. Cardiovascular comorbidity, in particular, is the focus of considerable research, due in part to the associated mortality and possible intervention. A common mechanism that may explain both psoriasis and atherosclerosis pathogenesis is of great interest and utility. The increase of Th1 and Th17 leading to chronic inflammation is thought to be a patho-denominator for both diseases. In addition, progressive adiposity and resultant metabolic syndrome are but the beginning steps in the "psoriatic march". In this article, we review the recent publications on cardiovascular risks in patients with psoriasis. We also examine the effects of psoriasis treatment, including the new biologics, on cardiovascular comorbidities. Although there is generally a lack of Asian research on this issue, we present the most recent pertinent findings from Taiwan.

17 Review Drug delivery and formulations for the topical treatment of psoriasis. 2008

Su, Yu-Han / Fang, Jia-You. ·Chang Gung University, Pharmaceutics Laboratory, Graduate Institute of Natural Products, 259 Wen-Hwa 1st Road, Kweishan, Taoyuan 333, Taiwan. ·Expert Opin Drug Deliv · Pubmed #18248321.

ABSTRACT: BACKGROUND: Psoriasis is one of the most common human skin diseases. It is characterised by excessive growth and aberrant differentiation of corneocytes, but is fully reversible with appropriate therapy. OBJECTIVE: There are many drug therapies for psoriasis via the topical delivery route. This review describes the topically applied drugs used to treat psoriasis. METHODS: Formulations to carry or encapsulate these drugs are introduced in this review. Enhancing approaches such as liposome inclusion, iontophoresis and laser are also discussed. CONCLUSION: This review summarises developments in the design of formulations in the area of topical drug delivery for treating psoriasis.

18 Clinical Trial Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. 2019

Bachelez, Hervé / Choon, Siew-Eng / Marrakchi, Slaheddine / Burden, A David / Tsai, Tsen-Fang / Morita, Akimichi / Turki, Hamida / Hall, David B / Shear, Michael / Baum, Patrick / Padula, Steven J / Thoma, Christian. ·Sorbonne Paris Cité Université Paris Diderot, Paris, France herve.bachelez@aphp.fr. · Monash University Malaysia, Johor Bahru, Malaysia. · Hedi Chaker University Hospital, Sfax, Tunisia. · University of Glasgow, Glasgow, United Kingdom. · National Taiwan University, Taipei, Taiwan. · Nagoya City University, Nagoya, Japan. · Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT. · Boehringer Ingelheim International, Biberach, Germany. · Boehringer Ingelheim International, Ingelheim, Germany. ·N Engl J Med · Pubmed #30855749.

ABSTRACT: -- No abstract --

19 Clinical Trial Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. 2019

Armstrong, April / Puig, Luis / Langley, Richard / Tsai, Tsen Fang / Song, Michael / Wasfi, Yasmine / Jiang, Jingzhi / Li, Shu / Han, Chenglong. ·a Keck School of Medicine , University of Southern California , Los Angeles , CA , USA. · b Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona , Barcelona , Spain. · c Dalhousie University , Halifax , Nova Scotia. · d National Taiwan University Hospital , Taipei , Taiwan. · e Janssen Research and Development, LLC , Spring House , PA , USA. ·J Dermatolog Treat · Pubmed #28797188.

ABSTRACT: PURPOSE: The Psoriasis Symptoms and Signs Diary (PSSD) is a patient-reported instrument that assesses severity of six symptoms (itch, skin tightness, burning, stinging, and pain) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of psoriasis. MATERIALS AND METHODS: PSSD symptoms and signs summary scores (range, 0-100) were derived based on individual item scores (0-10 [absent-worst imaginable]). Using Psoriasis Area and Severity Index [PASI], Investigator's Global Assessment [IGA] and Dermatology Life Quality Index [DLQI]) data from the NAVIGATE trial of patients with moderate-to-severe psoriasis, analyses were conducted to further validate the PSSD (7-day recall version) and establish criteria for clinically meaningful improvements (CMIs). RESULTS: Mean PSSD symptoms and signs summary scores were 50.6 and 60.7, respectively, at baseline, with no major floor (score of 0) or ceiling (maximum score) effects. PSSD scores and changes in PSSD scores were highly correlated with PASI, IGA, and DLQI scores (most Spearman's correlation r's ≥0.4, all p < .001). A 2-grade improvement in IGA or an improvement of 75%-<90% in PASI was associated with CMIs of ≥40-points in PSSD summary scores and ≥3-5-points in individual item scores. CONCLUSIONS: The PSSD possesses strong psychometric properties and is suitable for use as a measure of disease severity in clinical studies of patients with moderate-to-severe psoriasis.

20 Clinical Trial Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial. 2018

Lin, Y-K / See, L-C / Huang, Y-H / Chi, C-C / Hui, R C-Y. ·Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan. · School of Traditional Chinese Medicine, Chang Gung University, Taoyuan, Taiwan. · Department of Public Health and Biostatistics Core Laboratory, Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan. · Department of Rheumatology and Allergy and Immunology, Chang Gung Memorial Hospital, Linkou, Taiwan. · Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan. · College of Medicine, Chang Gung University, Taoyuan, Taiwan. ·Br J Dermatol · Pubmed #28815560.

ABSTRACT: BACKGROUND: Indigo naturalis and its refined formulation, Lindioil, are effective in treating psoriatic symptoms topically. Indirubin is the active ingredient in indigo naturalis. OBJECTIVES: To determine the efficacy and safety of different concentrations of indirubin in Lindioil ointment for treating psoriasis. METHODS: In this randomized, double-blind trial, adult patients presenting with chronic plaque psoriasis for > 1 year and with < 20% of the body surface area (BSA) affected were randomized to apply Lindioil ointment containing 200, 100, 50 or 10 μg g RESULTS: The results from week 8 revealed that the 200 μg g CONCLUSIONS: An amount of 200 μg g

21 Clinical Trial Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. 2018

Langley, R G / Tsai, T-F / Flavin, S / Song, M / Randazzo, B / Wasfi, Y / Jiang, J / Li, S / Puig, L. ·Department of Dermatology, Dalhousie University, Halifax, Nova Scotia, Canada. · Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan. · Dermatology, Janssen Research & Development, LLC, Spring House, PA, U.S.A. · Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. ·Br J Dermatol · Pubmed #28635018.

ABSTRACT: BACKGROUND: Guselkumab, an anti-interleukin-23 monoclonal antibody, has demonstrated significant efficacy in phase III psoriasis trials. OBJECTIVES: To evaluate the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis who had an inadequate response to ustekinumab. METHODS: In this phase III, randomized, double-blind study, 871 patients received open-label ustekinumab (45 mg or 90 mg) at weeks 0 and 4. At week 16, 268 patients with an inadequate response to ustekinumab [Investigator's Global Assessment (IGA) ≥ 2] were randomized (double-blind) to guselkumab 100 mg or to continue ustekinumab; 585 of 871 patients (67%) with IGA 0/1 at week 16 continued open-label ustekinumab. The primary end point was the number of visits at which randomized patients achieved IGA 0/1 and at least a two-grade improvement (from week 16) from week 28 to week 40. Improvement ≥ 90% or 100% in Psoriasis Area and Severity Index (PASI 90/100) and Dermatology Life Quality Index (DLQI) of 0/1 were also assessed. RESULTS: The mean number of visits at which patients achieved IGA 0/1 and at least a two-grade improvemen (week 28-40) was significantly greater in the guselkumab group vs. the randomized ustekinumab group (1·5 vs. 0·7; P < 0·001); greater proportions of patients in the guselkumab group achieved IGA 0/1 and at least a two-grade improvement at week 28 (31·1% vs. 14·3%; P = 0·001) and week 52 (36·3% vs. 17·3%; P < 0·001). Greater proportions of patients treated with guselkumab achieved PASI 90, PASI 100 and DLQI 0/1 at week 52. After week 16, 64·4% of patients in the guselkumab group and 55·6% in the ustekinumab group had at least one adverse event (AE); infections were the most frequent AE type. Overall, 6·7% (n = 9) of patients in the guselkumab group had at least one serious AE compared with 4·5% (n = 6) for the ustekinumab group. CONCLUSIONS: Patients treated with ustekinumab who did not achieve an IGA of 0/1 by week 16 derived significant benefit from switching to guselkumab.

22 Clinical Trial The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study. 2017

Zhang, JianZhong / Tsai, Tsen-Fang / Lee, Min-Geol / Zheng, Min / Wang, Gang / Jin, HongZhong / Gu, Jun / Li, RuoYu / Liu, QuanZhong / Chen, Jin / Tu, CaiXia / Qi, ChunMei / Zhu, Hua / Ports, William C / Crook, Tim. ·Peking University People's Hospital, Department of Dermatology, Beijing, China. Electronic address: rmzjz@126.com. · National Taiwan University Hospital, Department of Dermatology, Taipei, Taiwan. Electronic address: tftsai@yahoo.com. · Yonsei University College of Medicine, Department of Dermatology, Seoul, Republic of Korea. Electronic address: mglee@yuhs.ac. · Second Affiliated Hospital School of Medicine, Zhejiang University, Department of Dermatology, Hangzhou, Zhejiang, China. Electronic address: minz@zju.edu.cn. · Xijing Hospital, The Fourth Military Medical University, Department of Dermatology, Xi'an, Shaanxi, China. Electronic address: xjpfwanggang@163.com. · Peking Union Medical College Hospital, Department of Dermatology, Beijing, China. Electronic address: jinhongzhong@263.net. · Changhai Hospital, The Second Military Medical University, Department of Dermatology, Shanghai, China. Electronic address: gujun79@163.com. · Peking University First Hospital, Department of Dermatology, Beijing, China. Electronic address: mycolab@126.com. · Tianjin Medical University General Hospital, Department of Dermatology, Tianjin, China. Electronic address: liuquanzhong@medmail.com.cn. · Sichuan Provincial People's Hospital, Institute of Dermatology, Chengdu, Sichuan, China. Electronic address: chenjin99114@sina.com. · The Second Affiliated Hospital of Dalian Medical University, Department of Dermatology, Dalian, Liaoning, China. Electronic address: tucx2003@163.com. · Development China, GPD, Pfizer Investment Co. Ltd., Beijing, China. Electronic address: ChunMei.Qi@Pfizer.com. · Pfizer Development China, Shanghai, China. Electronic address: hua.zhu@pfizer.com. · Pfizer Inc., Groton, CT, USA. Electronic address: william.c.ports@pfizer.com. · Pfizer Ltd., Tadworth, United Kingdom. Electronic address: Tim.Crook@pfizer.com. ·J Dermatol Sci · Pubmed #28558978.

ABSTRACT: BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor. OBJECTIVE: This study assessed tofacitinib efficacy and safety vs placebo in Asian patients with moderate to severe chronic plaque psoriasis. METHODS: Patients from China mainland, Taiwan, and Korea were randomized 2:2:1:1 to tofacitinib 5mg (N=88), tofacitinib 10mg (N=90), placebo→5mg (N=44), or placebo→10mg (N=44), twice daily (BID) for 52 weeks. Placebo-treated patients advanced to tofacitinib at Week 16. Co-primary efficacy endpoints: proportions of patients achieving Physician's Global Assessment (PGA) response ('clear' or 'almost clear') and proportion achieving ≥75% reduction from baseline Psoriasis Area and Severity Index (PASI75) at Week 16. RESULTS: At Week 16, more patients achieved PGA and PASI75 responses with tofacitinib 5mg (52.3%; 54.6%) and 10mg (75.6%; 81.1%) BID vs placebo (19.3%; 12.5%; all p<0.0001). Of patients with a Week 16 response, 73.6% and 75.0% maintained PGA response, and 76.8% and 84.9% maintained PASI75 to Week 52 with tofacitinib 5mg and 10mg BID, respectively. Over 52 weeks, 2.2-4.5% of patients across treatment groups experienced serious adverse events, and 1.1-6.8% discontinued due to adverse events. CONCLUSION: Tofacitinib demonstrated efficacy vs placebo at Week 16 in Asian patients with moderate to severe plaque psoriasis; efficacy was maintained through Week 52. No unexpected safety findings were observed. [NCT01815424].

23 Clinical Trial Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study. 2017

Wu, Nan-Lin / Hsu, Chih-Jung / Sun, Fang-Ju / Tsai, Tsen-Fang. ·Department of Medicine, Mackay Medical College, New Taipei City, Taiwan. · Department of Dermatology, MacKay Memorial Hospital, Taipei, Taiwan. · Mackay Junior College of Medicine, Nursing, and Management, New Taipei City, Taiwan. · Department of Dermatology, China Medical University Hospital, Taichung, Taiwan. · Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan. · Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. ·J Dermatol · Pubmed #28493369.

ABSTRACT: The efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has been evaluated for moderate to severe plaque psoriasis in global trials which have included a low proportion of Asian subjects. We analyzed the efficacy and safety of secukinumab in Taiwanese patients in a phase III global clinical trial (ERASURE). Fifty-one Taiwanese patients were randomized into s.c. placebo, 150 and 300 mg secukinumab treatment groups. The proportions of patients who achieved 75% or more improvement in Psoriasis Area and Severity Index (PASI-75) at week 12 were 87.5% with 300 mg secukinumab, 70% with 150 mg secukinumab, 0% with placebo. Of the patients receiving 300 mg secukinumab, 68.8% achieved PASI-90 at week 12. Analysis of overall patients receiving 300 mg secukinumab for 12 weeks showed that the proportion of PASI-75 responders was less in patients with body mass index of 25 or more than less than 25. During the entire 52 weeks, the incidence of adverse events (AE) was consistent with the overall population in ERASURE. The most common AE (cases/per 100 patient-year) during the entire treatment period were upper respiratory tract infection and pruritus. The duration of upper respiratory tract infection per 100 patient-year was approximately 399 days in placebo, 1261 days in 150 mg secukinumab and 1805 days in 300 mg secukinumab. The safety and efficacy of secukinumab in Taiwanese patients was compatible with the global phase III study in the treatment of moderate to severe plaque psoriasis.

24 Clinical Trial Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. 2017

Blauvelt, Andrew / Reich, Kristian / Tsai, Tsen-Fang / Tyring, Stephen / Vanaclocha, Francisco / Kingo, Külli / Ziv, Michael / Pinter, Andreas / Vender, Ronald / Hugot, Sophie / You, Ruquan / Milutinovic, Marina / Thaçi, Diamant. ·Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com. · Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany. · National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. · University of Texas Health Science Center at Houston, Center for Clinical Studies, Houston, Texas. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Dermatology Clinic, Tartu University Hospital, Tartu, Estonia. · Emek Medical Center, Afula, Israel. · Goethe Universität Frankfurt am Main, Frankfurt, Germany. · McMaster University, Hamilton, Ontario, Canada. · Novartis Pharma AG, Basel, Switzerland. · Novartis Beijing Novartis Pharma Co. Ltd, Shanghai, China. · Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany. ·J Am Acad Dermatol · Pubmed #27663079.

ABSTRACT: BACKGROUND: Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis. OBJECTIVE: To compare the efficacy and safety of secukinumab and ustekinumab use over 52 weeks. METHODS: Analysis of 52-week data from CLEAR, a randomized, double-blind, phase 3b study. RESULTS: Among 676 randomized subjects, secukinumab demonstrated superiority to ustekinumab at week 52 in the proportion of subjects with ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) (76% vs 61% [P < .0001]); PASI 100 responses were 46% versus 36% (P = .0103) and Investigator's Global Assessment responses of clear/almost clear skin were 80% versus 65% (P < .0001). Subjects on secukinumab reported greater reductions in psoriasis-related pain, itching, and scaling, and greater improvement across all quality-of-life measures evaluated (Dermatology Life Quality Index [DLQI], EuroQoL 5-Dimension Health Questionnaire, Work Productivity and Activity Impairment Questionnaire-Psoriasis, and Health Assessment Questionnaire-Disability Index). At week 52, 72% of subjects on secukinumab versus 59% on ustekinumab (P = .0008) reported no impact of skin disease on their lives (DLQI 0/1 response). Safety and tolerability was comparable. LIMITATIONS: There was no placebo arm. CONCLUSION: In this head-to-head, double-blind study, secukinumab demonstrated sustained superior efficacy in comparison with ustekinumab in clearing skin through week 52, greater improvement in quality of life, and a favorable and comparable safety profile.

25 Clinical Trial Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. 2015

Thaçi, Diamant / Blauvelt, Andrew / Reich, Kristian / Tsai, Tsen-Fang / Vanaclocha, Francisco / Kingo, Külli / Ziv, Michael / Pinter, Andreas / Hugot, Sophie / You, Ruquan / Milutinovic, Marina. ·Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany. Electronic address: diamant.thaci@uksh.de. · Oregon Medical Research Center, Portland, Oregon. · Dermatologikum Hamburg and Georg-August-University Göttingen, Göttingen, Germany. · National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. · Hospital 12 de Octubre, Av de Córdoba, Madrid, Spain. · Clinic of Dermatology, Tartu University Hospital, Department of Dermatology, University of Tartu, Tartu, Estonia. · Department of Dermatology, Ha'Emek Medical Center, Afula, Israel. · University of Frankfurt, Frankfurt, Germany. · Novartis Pharma AG, Basel, Switzerland. · Beijing Novartis Pharma Co. Ltd, Shanghai, China. ·J Am Acad Dermatol · Pubmed #26092291.

ABSTRACT: BACKGROUND: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study). OBJECTIVE: We sought to directly compare efficacy and safety of secukinumab versus ustekinumab. METHODS: In this 52-week, double-blind study (NCT02074982), 676 subjects were randomized 1:1 to subcutaneous injection of secukinumab 300 mg or ustekinumab per label. Primary end point was 90% or more improvement from baseline Psoriasis Area and Severity Index (PASI) score (PASI 90) at week 16. RESULTS: Secukinumab (79.0%) was superior to ustekinumab (57.6%) as assessed by PASI 90 response at week 16 (P < .0001). The 100% improvement from baseline PASI score at week 16 was also significantly greater with secukinumab (44.3%) than ustekinumab (28.4%) (P < .0001). The 75% or more improvement from baseline PASI score at week 4 was superior for secukinumab (50.0%) versus ustekinumab (20.6%) (P < .0001). Percentage of subjects with the Dermatology Life Quality Index score 0/1 (week 16) was significantly higher with secukinumab (71.9%) than ustekinumab (57.4%) (P < .0001). The safety profile of secukinumab was comparable with ustekinumab and consistent with pivotal phase III secukinumab studies. LIMITATIONS: The study was not placebo-controlled and of short-term duration. CONCLUSIONS: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe psoriasis and improving health-related quality of life with a comparable safety profile over 16 weeks.

Next